wisp tirzepatide Shows Superior Weight Loss Over Semaglutide in Phase 3 Trial 22% body weight Tirzepatide | DirectMeds

For the study, researchers followed 195 adults with obesity for a year after they went on an initial low-calorie diet

The 87% success rate for achieving A1C below 7.0% exceeds what most diabetes medications accomplish as monotherapy

Injectable protocols (typically 1-2 mg administered subcutaneously, 5 days on/2 days off) should be reserved for advanced users working with knowledgeable clinicians who can monitor your copper status and watch for any adverse effects

Recently, drugs in both of these antidiabetic classes have been shown to reduce cardiovascular events, most likely by different mechanisms

Front Endocrinol 8:6 Christensen M, Knop FK, Vilsbll T, Holst JJ (2011) Lixisenatide for type 2 diabetes mellitus